A Study Testing the Drug Zanzalintinib for Meningioma That Has Come Back or Is Growing
Official title: A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial is testing a drug called zanzalintinib in people whose meningioma has come back or keeps growing.
Read our full plain-language summary
What the trial team says
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Key facts
- Registry number
- NCT07428616
- Stage of testing
- Phase 2
- Conditions studied
- Meningioma
Where it is running
This trial lists 12 sites.
-
Alabama
- University of Alabama (Birmingham)
-
Arizona
- Mayo Clinic_Arizona (Phoenix)
-
Florida
- Mayo Clinic_Jacksonville (Jacksonville)
- Baptist Health Miami Cancer Institute (Miami)
-
Missouri
- Washington University School of Medicine (St Louis)
-
New York
- Memorial Sloan-Kettering Cancer Center (New York)
- Mayo Clinic_Rochester (Rochester)
-
North Carolina
- Duke University (Durham)
-
Texas
- UT MD Anderson Cancer Center (Houston)
- UT Health San Antonio Mays Cancer Center (San Antonio)
-
Virginia
- Inova Center for Personalized Health (Fairfax)
-
Wisconsin
- UW Carbone Cancer Center (Madison)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.